




Background:  Treatment with highly active antiretroviral therapy (HAART) slows the progression of Human Immunodeficiency Virus (HIV) thus extending the life of people infected with HIV.  However, an increased incidence in dyslipidemia seen with HAART use may lead to increased cardiovascular disease (CVD) risk.
Objective:  To characterize the relationship between lipid and adipokine serum levels in HIV-infected men on HAART across disease progression and treatment at 5 time points:  preseroconversion, postseroconversion/pre-HAART, HAART initiation and two post HAART visits.  
Methods:  We measured serum levels of leptin, adiponectin, resistin, IL-6 and TNF-alpha in 54 HIV-infected men from the Multicenter AIDS Cohort Study (MACS). Mixed model repeated measures ANOVA and bootstrap correlation quantify the relationships between the adipokine and lipid levels.  
Results:  Adiponectin decreased post-seroconversion and post HAART initiation and remained lower throughout the HAART visits.  TNF-alpha and IL-6 increased at seroconversion and HAART initiation and then decreased with continued therapy.   Adiponectin and HDL-C were significantly positively correlated at every time point except post-seroconversion.  The other adipokines were not correlated with any of the lipid measures.
Conclusions: The relationship between adiponectin and HDL-C is changed with HIV infection and HAART; potentially reflecting metabolic and cardiovascular complications that seen during the course of the disease-treatment process.
Public health significance:  Exploring the role adipokines play in metabolic pathway disturbances in relationship to HIV infection and HAART has important public health significance by elucidating potential leading to drug therapy targets to reduce CVD risks.
TABLE OF CONTENTS
 TOC \o "2-4" \h \z \t "Heading 1,1,Appendix,1,Heading,1" prefacE	x
1.0	INTRODUCTION	1
1.1	Epidemiology of hiv infection	2
1.2	pathophysiology of HIV Infection	3
1.3	HAART, LIPid metabolism and cvd risk	3
1.4	Role of adipokines	5
2.0	methods	8




2.5	Timing of data collected	11
2.6	Statistical analysis	12
3.0	REsults	13
3.1	summary of changes in biomarkers over time	13




3.1.5	Incorporating BMI and Age	15
3.2	Relationship between adipokines and lipids	16
4.0	Discussion	20
4.1	change in adipokines levels	20
4.2	Contribution to current knowledge of lipid metabolism	21




 TOC \h \z \c "Table" Table 1.  Time between visits	12
Table 2.  Cardiovascular Biomarker Levels [mean (SE)]	13
Table 3. Cardiovascular Biomarker Levels:  Correlations (n=10,000 Bootstrap samples)	16
Table 4. Coefficient of Variation for Cytokine Analyses	23
List of figures
 TOC \h \z \c "Figure" Figure 1: Schematic of Lipid Metabolism and the various roles of Leptin and Adiponectin (from Lago et al)	6
Figure 2:  Time between visits	11
prefacE 






Treatment of the Human Immunodeficiency Virus (HIV) with Highly Active Anti-Retroviral Therapy (HAART) has dramatically slowed the progression of the disease into Acquired Immunodeficiency Syndrome (AIDS).  Swift initiation of HAART, once HIV-infection has been identified in a patient, has changed the epidemiologic profile of HIV.  Once a deadly infectious disease with a myriad of debilitating co-morbidities, such as opportunistic secondary infections like Hepatitis–B or –C, or HIV-associated cancer – Kaposi’s sarcoma, it now has a chronic disease-like epidemiologic profile with more manageable co-morbidities [1].  With extended life expectancies for those living with HIV infection, researchers and clinicians are now focusing on the long-term effect of HIV infection and HAART side effects.  
Dyslipidemia, characterized by abnormal serum lipid levels, is a common disorder of aging that potentially leads to atherosclerosis and is a risk factor for Cardiovascular Disease (CVD).    The prevalence of dyslipidemia in HIV-infected patients on HAART ranges from 20-80% in different studies ADDIN EN.CITE [2]  ADDIN EN.CITE [3] and also occurs at a younger age, sometimes as early as their mid-30’s compared to mid-50’s as in the general population  ADDIN EN.CITE [2].  Adipokines, biologically active hormones produced by adipose tissue, have been studied for their role in lipid metabolism [4],  dyslipidemia  ADDIN EN.CITE [5] and metabolic syndrome in the general population  ADDIN EN.CITE [4, 6].Researchers found that adipokines could be used as biologic therapies to help balance perturbations [7] in lipid metabolism due to genetics, aging or other disease processes  ADDIN EN.CITE [8]  ADDIN EN.CITE [5].  
Our aim is to characterize the relationship between lipid, adipokine and cytokine serum levels in HIV-infected men on HAART through disease progression and treatment represented by different clinic visits occurring from preseroconversion to postseroconversion/pre-HAART and then after HAART initiation.  
1.1	Epidemiology of hiv infection
HIV infection causes a considerable health burden in the United States.  In 2010, an estimated 48,079 adults and adolescents were diagnosed with HIV infection; of these, 79% of diagnoses were among males and 21% were among females. The incidence rate of HIV infection among both males and females remained stable from 2007-2010 [9].  With the exception of certain sub-groups, whose infection rates are much higher, the incidence of HIV infection has been stable at 50,000 new infections per year.  Heterosexuals accounted for 25% of estimated new HIV infections in 2010 and 27% of people living with HIV infection in 2009.  Gay, bisexual, and other men who have sex with men (MSM) are most seriously affected by HIV.  Compared to other races or ethnicities, African Americans/blacks continue to experience the most severe burden from HIV.  An estimated 15,529 people with an AIDS diagnosis died in 2010, and approximately 636,000 people in the United States with an AIDS diagnosis have died since the beginning of the epidemic [10].  The deaths of persons with an AIDS diagnosis can be due to any cause – that is, the death may or may not be related to AIDS.  
1.2	pathophysiology of HIV Infection
HIV attacks the immune system, specifically CD4 T-lymphocytes.  The virus uses the host immune cell to replicate, killing the cells in the process.  A person newly infected with HIV, known as acute infection, can experience mild flu-like symptoms as a result lasting only a few months [11], During acute infection, antibodies to HIV can be detected in the blood, a process known as seroconversion.  After acute infection, the virus becomes dormant, referred to as the latent period, which may last several years to over a decade, depending on the infected individual’s genetics, physical stressors, pre-existing co-morbid disease and overall general health.  Eventually the virus becomes active, replicates, depleting the infected host’s immune cells, and the person enters the final stage of HIV disease, commonly known as AIDS.  As the viral load increases, the number of CD4 cells decrease.   Because of this, CD4 cell count is commonly used as a surrogate for severity of infection.  When CD4 cell count drops to <200cells/µl, an infected person is then considered to have developed AIDS. 
1.3	HAART, LIPid metabolism and cvd risk
In 1981, at the beginning of the HIV/AIDS epidemic, anti-viral therapies were available but they were not very effective at slowing the progression of HIV infection [11].  When HAART became available for HIV infection in 1996, patients who were hospitalized and/or bedridden, after taking the medication, were up and walking around the next day, thus making HAART seem to have a miraculous “Lazarus Effect”.  HAART successfully slowed the incidence of HIV infection and reduced deaths from AIDS over the next 10 years [12]  ADDIN EN.CITE [6]; however, metabolic co-morbidities and CVD risk were rising in the HIV infected, HAART treated, aging population.
Metabolic co-morbidities impair the ability of cells to obtain energy that is needed for them to survive.  That energy is derived from food in the form of glucose, lipids and proteins, or pulled from storage depots in the body.  Humans take excess glucose and store it as adipose tissue to use during famine.  Metabolic syndrome is a constellation of risk factors, increased blood pressure, dyslipidemia abdominal obesity and hyperglycemia) that tend to cluster together.  There is no consensus on what causes MS but many believe when these metabolic processes do not function properly and is associated with diabetes, insulin resistance, lipodystrophy and dyslipidemia. 
Patients on HAART, especially due to protease inhibitors, experience metabolic complications including dyslipidemia, high blood pressure, adipose redistribution and insulin resistance placing them at a higher risk for CVD and diabetes  ADDIN EN.CITE [6] [13].  The pathogenesis of metabolic syndrome in HIV-infected patients compared to other patients is very different.  In HIV-infected patients who are not considered obese, there is HAART-induced dyslipidemia, hypertriglyceridemia and HDL reduction where in non-HIV-infected patients hypertriglyceridemia and dyslipidemia stem from abnormal fat metabolism due to obesity.  Total cholesterol (TC), low density lipoprotein (LDL-C) and high density lipoprotein (HDL-C) levels fall after seroconversion.  Lower levels of TC and LDL-C and higher levels of HDL-C are preferable.  The lipid levels increase after HAART initiation to slightly higher levels than those seen at preseroconversion with the exception of HDL-C, which remains lower. TC, LDL-C and triglycerides (TG) remain higher than preseroconversion levels as treatment continues but HDL-C still remains lower [14].  Adipose redistribution, lipodystrophy (LD), manifests itself in peripheral fat wasting, back of neck and breast fat accumulation and increase in waist circumference  ADDIN EN.CITE [5] [15]  ADDIN EN.CITE [16].  Patients on HAART experience metabolic complications including dyslipidemia, adipose redistribution and insulin resistance which place these patients at a higher risk for cardiovascular disease and diabetes  ADDIN EN.CITE [2].  The prevalence of insulin resistance and diabetes mellitus increase the longer HIV infected men continue on HAART  ADDIN EN.CITE [17] at a higher rate than non-infected men.  
1.4	Role of adipokines
Researchers are actively investigating the role adipokines have on pathophysiologic and metabolic changes in HIV-infected men on HAART [4].  Cytokines secreted by adipose tissue (IL-6 and TNF-alpha) or adipokines (leptin, adiponectin, and resistin) are potential mediators between lipid dysfunction and metabolic syndrome as illustrated in Figure 1 [7].  Adipokines are potential targets for deciphering pharmacological remedies that could help slow down or reverse the effects of HAART on CVD.

Figure 1: Schematic of Lipid Metabolism and the various roles of Leptin and Adiponectin (from Lago et al)
	Leptin was the first adipokine identified.  Through direct effects of the hypothalamus, leptin influences food intake, decreasing it and increasing energy consumption, with circulating levels directly correlating with adipose tissue  ADDIN EN.CITE [7, 18].  Having actions in the brain, peripheral tissues, as well as cells of the pancreas, liver and immune system, the central actions of this adipocyte-derived hormone include energy and glucose homeostasis, reproductive functions, and immunity  ADDIN EN.CITE [19].  In either non-infected or HIV-infected patients, the accumulating data support the proartherogenic, proinflammatory properties of leptin, showing that high levels of leptin increase the inflammatory milieu and the overall cardiovascular risk in the HIV-infected population [20].  Adiponectin has anti-inflammatory and antioxidant properties with direct anti-artherosclerotic effects [21].  HAART-induced hypoadiponectinemia in HIV-infected patients can lead to detrimental cardiovascular events via numerous metabolic mechanisms, including lipid profile, that deteriorate due to low adiponectin levels  ADDIN EN.CITE [22].  Rodent studies show resistin has an association with insulin resistance, diabetes and obesity, but these have not been consistent in human data [23].  In HIV-infected patients compared to uninfected individuals, resistin levels were higher.  Human resistin actually comes more from macrophages and mononuclear lymphocytes rather than adipocytes so in this manner resistin may contribute to inflammation cascades along the HIV-infected HAART use CVD pathophysiology tract [24].  TNF-alpha and IL-6 are systemic cytokines that are also produced by adipocytes.  They are known for their proinflammatory affects  ADDIN EN.CITE [25], impairment of insulin sensitivity and promotion of dyslipidemia.  It has been shown that IL-6, or other inflammatory stimuli, regulate leptin mRNA expression and its circulating levels [26].  TNF-alpha acts locally and is produced by macrophages and lymphocytes more so than adipocytes but still has strong influence on the inflammatory climate of the surrounding tissue.  
In exploring the relationship between lipid, adipokine and cytokine serum levels in HIV-infected men on HAART from the MACS cohort from preseroconversion through long-term HAART use, we aim to quantify which of these adipose derived substrates vary across disease and treatment progression and to relate these changes to the changes in lipid levels.

2.0 	methods
2.1	The Multicenter Aids Cohort Study (macs)
The Multicenter AIDS Cohort Study (MACS) is a multicenter prospective cohort of men that provides researchers with a unique opportunity to study the natural and subsequent treatment histories of HIV disease progression [12].  MACS started in 1984 and had three main recruitment periods (April 1984 – March 1985, April 1987 – September 1991, and October 2001 – August 2003).  The last recruitment cohort was implemented to assess the long term benefits and adverse effects of HAART therapy.  This study recruited men at risk for HIV infection, prior to seroconversion, and has over 16 years long term follow-up.   The study has enrolled over 6972 homosexual and bisexual men across four cities:  Pittsburgh, PA; Baltimore, MD; Los Angeles, CA; and Chicago, IL.  MACS data has been used in over 1300 scientific publications to date making significant contributions to the understanding of HIV, AIDS and effects of therapy.  
2.2	Study Objectives
This pilot study will ascertain whether certain adipokines and adipose related cytokines are associated with metabolic complications in HIV infected men on HAART.  We first measured the change in serum adipokine levels from preseroconversion through HAART treatment and compared them to lipid levels assessing correlation.  The goal is to capture the role of adipokines across HIV infection, initiation of HAART and development of adipose metabolism complications.  The main steps of this research included:  1) characterizing the change in adipokine (adiponectin, leptin, resistin, IL-6 and TNF-alpha) and lipid levels (TC, LDL-C and HDL-C) as HIV + men progress over 5 visits from preseroconversion through seroconversion and HAART therapy 2) characterizing the relationship between the adipokines and lipids at each time point.  The analysis is post-hoc and retrospective.
2.3	Sub-Study Population Sample
In MACS participant follow-up visits occurred every 6 months and included physical examination, blood sample collection and participant interview.  Each site has approval from their institutional review boards and written informed consent was obtained from all participants.  For this analysis, we identified a subset of 54 men with stored serum samples from five study visits that are defined by stages of disease and/or treatment at the time of the visit:
V1 – Preseroconversion – prior to acute infection, 
V2 – Postseroconversion – active infection detected in serum and may be on some type of treatment but still prior to HAART initiation, 
V3 – 1st HAART Visit:  6 months to 2 years after HAART initiation 
V4 – 2nd HAART Visit:   2-5years after HAART initiation
V5 – 3rd HAART Visit:  >5 years after HAART initiation.  
Seroconversion is defined as the point where HIV antibodies are first detectable in serum, marking active infection.  The initial period of active infection is typically followed by a long period of latency during which time seropositive individuals are symptom-free. This lasts on average for seven years before viral reactivation occurs and the individual progresses to AIDS.  Progression of disease and decision to start patients on HAART had the sample collection time points years apart on average and overlapping tremendously.  
This pilot study was motivated by the work done by Riddler et al (2003)[14], where they characterized changes in lipids preseroconversion through seroconversion and then subsequently treatment.  We expand this by characterizing changes in adipokine and cytokine levels in these patients and their relationship to the lipid measures.  This study and the Riddler study both analyzed data from 54 participants.  There are 32 participants that were common to both studies.  Due to a lack of available serum the desired time points, we use 22 participants not from the Riddler study.  Substitutes were selected mainly based on their serum availability at the desired time points.  The HAART definition for the purposes of our analysis were described previously  [14].
2.4	Laboratory Assays
Repository serum samples were tested at the Heinz Nutrition Laboratory, University of Pittsburgh in Pittsburgh, PA.  Leptin and total adiponectin levels were assessed by RIA (Radioimmune Assay) from LINCO Research (St. Charles, MO).  Resistin, IL-6 and TNF-alpha were assessed by Elisa from R&D Systems (Minneapolis, MN).  (Coefficient of variation – see appendix). TC level was measured using the enzymatic method[27] (coefficient of variation =1.3%).  HDL-C level was measured after selective heparin/manganese chloride precipitation and removal of very low-density lipoprotein and LDL-C by centrifugation[28] (coefficient of variation=2.1%). LDL-C level assessment was by direct measure via spectrophotometric assay[29] (LDL-C Direct Liquid Select, Equal Diagnostics, Exton, PA [coefficient of variation=2%]).  CD4 cell counts were determined per National Institute of Allergy and Infectious Diseases laboratory protocols by flow cytometry. ADDIN EN.CITE [30] 
2.5	Timing of data collected
Time in these samples is highly variable between subjects and within subjects.  Each patient had five blood draws selected for the pilot study.  To understand the variation in time between analysis points, we looked at the time between visit data as a box plot (Figure 2) and as a table (Table 1).    The range of time between postseroconversion and 1st HAART is the longest with 15.5 years and the shortest is between 1st HAART and 2nd HAART, with 4.5 years. 
Figure 2:  Time between visits

Table 1.  Time between visits

	Time (yrs) between preseroconversion and seroconversion	Time (yrs) between postseroconversion and 1st HAART	Time (yrs) between 1st HAART and  2nd HAART	Time (yrs) between 2nd HAART and  3rd HAART
Mean	6.8    	4.2  	2.3	3.1   






Analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC).  Mixed model ANOVA with repeated measures was used to compare the adipokine, cytokine and lipid values across time, however this did not take into account the variation between the time points themselves and the time points from patient to patient.  Pearson correlation and bootstrapping were used to assess the mean correlation and mean confidence intervals between the adipokines and lipid levels so that the changes in the correlations from time point to time point could be compared.  Multiple correlations from 10,000 samples were used and the mean r and mean confidence intervals was reported.      
3.0 	 REsults
3.1	summary of changes in biomarkers over time
Table 2 shows the adipokines (leptin, adiponectin and resistin), cytokines (IL-6 and TNF-alpha) and lipids (total cholesterol, LDL-C and HDL-C) unadjusted and adjusted for BMI and age at visit.  
Table 2.  Cardiovascular Biomarker Levels [mean (SE)] 
	Presero-conversion 	Postsero-conversion	1st visit after HAART initiation	2nd visit after HAART initiation	3rd visit after HAART initiation	RepeatedMeasures ANOVA  p-value	Adjusted Repeated Measures ANOVA  p-value
Leptin (ng/mL)	3.8 (0.51)	3.7 (0.53)	3.8 (0.52)	3.8 (0.52)	4.8 (0.52)	0.70	0.20
Adiponectin (µg/mL)	12.1 (0.78)	10.9 (0.80)	9.1 (0.78)	9.1 (0.78)	9.1 (0.79)	0.01*	<.01*
Resistin (ng/mL)	12.1 (0.99)	10.5 (1.02)	11.5 (0.99)	11.3 (0.99)	12.8 (1.02)	0.30	0.53
IL-6 (pg/mL)	1.5 (0.60)	2.8 (0.62)	3.1 (0.60)	2.5 (0.60)	2.5 (0.61)	<.01*	0.36
TNF-alpha (pg/mL)	1.7 (0.93)	3.0 (0.96)	4.2 (0.93)	2.1 (0.96)	1.9 (0.95)	<.01*	0.21
Total Cholesterol (mg/dL)	195 (6.8)	173 (7.4)	211 (6.7)	213 (6.5)	201 (6.6)	<.01*	<.01*
LDL-C (mg/dL)	116 (5.1)	109 (5.5)	120 (5.0)	118 (4.8)	112 (4.9)	0.87	0.87
HDL-C (mg/dL)	48 (1.9)	41 (2.0)	42 (1.8)	44 (1.8)	43 (1.8)	0.04*	0.03*
CD4 cell count	1100 (37.9)	412 (37.6)	463 (36.8)	490 (36.5)	527 (37.2)	<.01*	--
Age at visit (years)	35 (1.1)	42 (1.2)	46 (1.1)	48 (1.1)	51 (1.0)	<.01*	--
BMI	24.1 (0.46)	24.8 (0.47)	25.2 (0.46)	25.0 (0.46)	25.3 (0.47)	0.37	--
* p-value of significance
1.1.1	Change in Clinical Characteristics
Age varied significantly across visits as expected.  The mean age of participants at entry to the study in this small sub-set was 35.  By the 3rd HAART visit, the mean age was 51.
BMI did not change significantly across visits.  HIV-infected men, regardless of HAART and/or PI status, often experience one or both lean muscle mass wasting and body fat redistribution during the disease course.  BMI changed only 0.5 kg/cm2over the time points after seroconversion, thus showing that the change in overall BMI was not changing with active infection or HAART treatment.  However, BMI is not indicative of type or location of fat or muscle deposition which could change without having a net change in overall body mass.  
CD4 cell count changed across visits as expected, being the highest at preseroconversion, before infection was detectable and lowest postseroconversion, after active infection and prior to HAART. HAART treatment increases CD4 cell count slightly at the first HAART visit and it continues to increase, however after 3-6 years at the 3rd HAART visit, the CD4 cell count is still 50 to 60% of what it was before seroconversion.  
1.1.1	Change in Adipokines
Changes in unadjusted leptin and resistin were minimal.  In the literature, resistin has had stronger association with glucose and insulin resistance  ADDIN EN.CITE [17] than with dyslipidemia.  However, it is surprising that the overall p-value for leptin was not statistically significant (p=0.70) since leptin is generally believed to be strongly correlated with fat and it plays a major role in fat metabolism.  The leptin levels are similar for the first four visits and with an increase at the 3rd HAART visit.  One possibility is that another biomarker not considered here is having an effect on leptin and maybe it has more influence. 
The overall unadjusted adiponectin levels changed significantly across the visits.  Adiponectin decreased between postseroconversion and 1st HAART visit.  There was no change between the HAART visits in the adiponectin levels.
1.1.1	Change in Cytokines
IL-6 and TNF-alpha unadjusted levels are significantly changed across all of the visits.  IL-6 and TNF-alpha levels increased at post-seroconversion and again at the 1st HAART visit.  Their levels then decrease as patients continue on HAART, with TNF-alpha almost returning to preseroconversion levels.  These biomarkers are systemic cytokines as well as being produced in adipose tissue.  They become elevated during the body’s immune response which is consistent with changes seen due to HIV and HAART.  
1.1.1	Change in Lipids
Changes in LDL-C were small from that of preseroconversion.  Change in total cholesterol and HDL-C levels had statistically significant p-values, <.01 and 0.04 respectively, across the visits.  Total cholesterol levels drop markedly from pre- to postseroconversion then increase at the 1st HAART visit to a level slightly higher than preseroconversion level, a phenomenon that many researchers have seen previously and attribute to the use of protease inhibitors in the HAART cocktail.  This is slightly higher than the normal to borderline high total cholesterol values [31] for treatment of hypercholesterolemia.  At the 2nd HAART visit, total cholesterol level is similar to that of the 1st HAART visit level but still over the borderline level cutoff.  The 3rd HAART visit level is slightly higher that the 1st two and still in the borderline range.  HDL-C levels drop markedly from pre- to postseroconversion.  Lower HDL-C levels increase cardiovascular disease risk.  From postseroconversion through the three HAART visits, the HDL-C levels increase slightly, but do not return to preseroconversion levels.
1.1.1	Incorporating BMI and Age
There were some differences in the changes in biomarker levels between visits for the adjusted versus unadjusted biomarker levels.  Adiponectin, total cholesterol and HDL-C levels are still statistically significant and leptin, resistin, LDL-C levels are still not statistically significant.  Changes in IL-6 and TNF-alpha, which were statistically significant when unadjusted, were no longer statistically significant when adjusted for age at visit and BMI.  This difference in the significance of the change through the time points are most likely attributable to age at visit since the change in BMI across time points was not significant but the change in age at visit across time points was statistically significant.  By adjusting for age at visit, we are eliminating the portions of IL-6 and TNF that are being produced from the typical effects of aging.  Life expectancies for those who are HIV-infected have increased markedly, much of which can be attributed to HAART.  
1.1	Relationship between adipokines and lipids
Partial correlations adjusting for participant’s BMI at the time of the visit did not differ from the correlations without such adjustment (results are not shown).  Adipokine/cytokine and lipid pairs are in Table 3.  

Table 3. Cardiovascular Biomarker Levels:  Correlations (n=10,000 Bootstrap samples)
Leptin
Time point	Total Cholesterol	LDL-C	HDL-C
	r	95% CI	r	95% CI	r	95% CI
preseroconversion	0.14	-0.08 to 0.34	0.21	-0.13 to 0.47	0.11	-0.3 to 0.09
postseroconversion	0.14	-0.19 to 0.48	-0.01	-0.24 to 0.34	0.02	-0.16 to 0.26
1st HAART	-0.11	-0.35 to 0.19	-0.17	-0.41 to 0.11	0.03	-0.21 to 0.3
2nd HAART	-0.04	-0.36 to 0.31	-0.06	-0.33 to 0.23	0.2	-0.03 to 0.42




	r	95% CI	r	95% CI	r	95% CI
preseroconversion	0.25	-0.07 to 0.53	0.23	-0.06 to 0.52	0.48	0.16 to 0.76*
postseroconversion	0.11	-0.21 to 0.43	0.01	-0.24 to 0.39	0.11	-0.18 to 0.56
1st HAART	0.10	-0.35 to 0.18	0.12	-0.16 to 0.42	0.35	0.14 to 0.56*
2nd HAART	0.22	-0.05 to 0.47	0.36	0.16 to 0.56*	0.27	0.04 to 0.51*
3rd HAART	0.01	-0.26 to 0.27	0.12	-0.16 to 0.38	0.42	0.23 to 0.59*




	r	95% CI	r	95% CI	r	95% CI
preseroconversion	 0.03	-0.21 to 0.15	 0.06	-0.26 to 0.14	 0.01	-0.29 to 0.32
postseroconversion	 0.01	-0.21 to 0.22	 0.01	-0.15 to 0.24	 0.05	-0.19 to 0.12
1st HAART	 0.01	-0.17 to 0.19	 0.02	-0.18 to 0.20	 0.15	-0.07 to 0.37
2nd HAART	 0.10	-0.12 to 0.35	 0.07	-0.27 to 0.15	 0.07	-0.33 to 0.23




	r	95% CI	r	95% CI	r	95% CI
preseroconversion	-0.17	-0.39 to -0.01*	-0.17	-0.39 to -0.01*	-0.07	-0.26 to 0.10
postseroconversion	-0.06	-0.26 to 0.24	-0.10	-0.26 to 0.19	-0.15	-0.32 to -0.06*
1st HAART	-0.06	-0.23 to 0.03	-0.05	-0.39 to 0.08	-0.15	-0.34 to 0.14
2nd HAART	 0.10	-0.13 to 0.37	 0.10	-0.10 to 0.29	-0.14	-0.38 to 0.20
3rd HAART	-0.30	-0.51 to -0.08*	-0.19	-0.48 to 0.12	-0.13	-0.31 to 0.06




	r	95% CI	r	95% CI	 R	95% CI
preseroconversion	0.03	-0.14 to 0.23	0.01	-0.19 to 0.25	-0.03	-0.20 to 0.12
postseroconversion	-0.10	-0.28 to 0.05	-0.13	-0.28 to 0.01	-0.11	-0.27 to -0.03*
1st HAART	-0.02	-0.19 to 0.20	0.02	-0.19 to 0.29	-0.20	-0.37 to 0.04
2nd HAART	-0.15	-0.30 to 0.06	-0.25	-0.44 to -0.03*	-0.27	-0.50 to -0.15*
3rd HAART	-0.04	-0.32 to 0.25	0.04	-0.28 to 0.19	-0.15	-0.44 to 0.17
*95% confidence interval of significance

Leptin and resistin are not highly correlated with any of the lipids.  Adiponectin is positively, correlated with a significant confidence interval with HDL-C during preseroconversion and when HAART is being given.  The correlation is reduced at postseroconversion and is no longer significant.  When HIV-infection is being managed, either in preseroconversion or by treatment, adiponectin and HDL-C are correlated with one another.  Adiponectin is correlated with LDL-C only at the 2nd HAART visit with a significant 95% confidence interval.  
IL-6 is statistically significantly, inversely correlated with total cholesterol at preseroconversion and the 3rd HAART visit.  IL-6 was statistically significantly, inversely correlated with LDL-C at preseroconversion only.  IL-6 was statistically significantly, inversely correlated with HDL-C at postseroconversion.  The correlations at 1st, 2nd and 3rd HAART were correlated as well but were not statistically significant.  
TNF-alpha was statistically significantly, inversely correlated at the 2nd HAART visit with LDL-C.  TNF-alpha was statistically significantly, inversely correlated at the 2nd HAART and postseroconversion with HDL-C. Of note, at preseroconversion the correlation is very low between TNF-alpha all of the lipid levels.  At the 3rd HAART visit, TNF-alpha had a low inverse correlation with total cholesterol, LDL-C was closer to preseroconversion levels, but HDL-C was higher than preseroconversion levels.
2.0 	Discussion
2.1	change in adipokines levels
Leptin levels remain about the same through the first four visits and then increase after long term (3-6 years) of HAART use.  Higher leptin levels are usually indicative of more adipose tissue.  Leptin or some pre-cursor may not respond properly in this setting to HIV infection plus HAART treatment over a longer time period.
Adiponectin levels vary over visits.  They decrease from preseroconversion to postseroconversion and again postseroconversion to 1st HAART and then level off between the HAART visits.  Adiponectin should be affected by BMI and BMI does not change much from visit to visit.  Its expression is suppressed in patients with obesity and type 2 diabetes, showing an inverse relationship with insulin resistance and visceral adiposity [4].  The lack of influence from BMI could be a product of the variation within the sampling time points.    Other studies have used waist circumference, waist to hip ratio, carotid artery thickness, visceral adipose tissue (VAT) vs. subcutaneous adipose tissue (SAT), and fat mass as measured by DEXA [32].
Resistin did not change over time in our analysis.  The previous human literature also showed that resistin was not associated with abnormalities of lipid metabolism.  IL-6 and TNF-alpha level, the pro-inflammatory cytokines, increased at postseroconversion and again at the 1st HAART visit, as these systemic cytokines, meaning not only fat based, becomes elevated during the body’s immune response.  Both IL-6 and TNF-alpha levels decrease as patients continue on HAART with TNF-alpha almost returning to preseroconversion levels. However, IL-6 remains higher than preseroconversion at the 3rd HAART visit.  These results suggest that adiponectin and IL-6 remain altered during HAART therapy while leptin, resistin and TNF-alpha return to preseroconversion levels.
2.2	Contribution to current knowledge of lipid metabolism
Time is confounded with the HIV infection process, HAART treatment and the natural process of aging.  Now that HIV infection is treatable and patients are surviving into old age, to incorporate the aging process and the associated conditions considering how to treat HIV patients.  Onset of heart disease is seen at younger ages in these patients.  Previous literature reports that resistin, IL-6 and TNF-alpha promote dyslipidemia while leptin and adiponectin inhibit dyslipidemia.  Adiponectin seems to have the most influence over the variation in HDL-C. HDL-C and adiponectin decrease from preseroconversion through treatment with HAART with the decreases slowing with more time on therapy. 
Hyperlipidemia, elevated total cholesterol and LDL-C can lead to atherosclerotic plaque formation, which can subsequently lead to myocardial infarction, ischemic stroke, or deep vein thrombosis.  Conversely, hypolipidemia is also suboptimal.  
2.3	Public Health Impact, Limitations and Conclusion
Since we were only looking at men in this study the results would not be generalizable to women or children with HIV infection.  Robust statistical methods were utilized to take into account repeated measures.  It would be warranted that future studies are better powered for prospective adipokines and cytokines measurements.  The nature of HIV infection, seroconversion onset, and HAART initiation timing limits how uniformly any time points can be planned, therefore continuing to use statistically sound analysis techniques to account for the variation will be necessary.  Adding adipokine analysis to large prospective studies such as MACS and better metabolic syndrome risk surrogates such as DEXA measured fat mass would be another option for future study design.  
	The public health impact of this work includes use of adipokines as novel therapies of metabolic syndrome in HIV infected men on HAART.  Reduction of HAART side effects such as dyslipidemia, fat re-distribution, insulin resistance, and vascular abnormalities, would lessen cardiovascular co-morbidities, increase compliance with HAART, and keep overall health care costs down.  Preventing or at least delaying the onset of cardiovascular co-morbidities will also increase quality of life and life expectancy in the process. 
APPENDIX: ADDITIONAL METHODS
Table 4. Coefficient of Variation for Cytokine Analyses

	Inter assay	Mean	Intra assay
Leptin (RIA) Linco	11%	15.0 uU/mL	9.60%
	5.8%	32.6 uU/mL	6.70%
Total Adiponectin (RIA) Linco	11.8%	80 ng/mL	8.20%
	18.5%	13.7 ng/mL	8.60%
Resistin (ELISA) Linco	17.6%	0.5 ng/mL	8.00%
	11%	>2.0 ng/mL	5.10%




Additional resources from the World Wide Web:
For more information about MACS:  http://www.statepi.jhsph.edu/macs/macs.html.
HIV statistics from the Centers for Disease Control – Basics at a Glance http://www.cdc.gov/hiv/statistics/basics/ataglance.html
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